Actionable insights straight to your inbox

logo_equities.svg

Telik Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material (Jun. 30, 2014)

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission

By a News Reporter-Staff News Editor at Pharma Business Week — According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Telik Inc. (Form DEFA14A) was posted on June 30, 2014.
The SIC code for this company is 2834, Pharmaceutical Preparations.
There was one document filed with this form. The SEC file number is 0001193125-14-254479.
The contact information for this company is 2100 GENG ROAD, SUITE 102, PALO ALTO CA 94303, 6508457700.
Our editors provided additional information about Form DEFA14A: Additional proxy soliciting materials-definitive.
A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.
For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/1109196/0001193125-14-254479-index.html.
Keywords for this news article include: Pharmaceutical Companies, Pharmaceutical Preparations, Telik Inc, SEC Filing.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

Many people think of position size in terms of how many shares they own of a particular stock. But it’s much smarter to think of it in terms of what percentage of your total capital is in a particular stock.